BSE announces securities being added to, moved within, and removed from the Short Term Additional Surveillance Measure (ST-ASM) framework effective October 27, 2025.
Impact
Medium
Severity
Medium
Justification
Affects 23+ securities with surveillance measure changes that impact trading conditions, but primarily involves smaller cap stocks with limited market-wide systemic impact
BSE announces securities shortlisted for Short Term ASM framework effective October 27, 2025, including 14 new securities and 9 securities moving out of the framework.
Impact
Medium
Severity
Medium
Justification
Affects trading parameters for 14 securities entering ST-ASM framework and 9 exiting, impacting liquidity and trading flexibility for investors in these stocks
BSE settlement notice for demat auction settlement number 741 dated October 24, 2025, listing securities and quantities for auction.
Impact
Medium
Severity
Medium
Justification
Routine settlement auction notice affecting multiple securities with varying quantities; impacts specific trading members with delivery obligations but is a standard market operation.
BSE demat auction settlement listing securities available for auction to fulfill delivery obligations, covering 117 scrips across various sectors.
Impact
Low
Severity
Low
Justification
Routine demat auction settlement notice with standard delivery obligation fulfillment process affecting specific scrips with limited market-wide impact
BSE Demat Auction circular listing securities and quantities subject to auction settlement for settlement number 738 dated October 20, 2025.
Impact
Medium
Severity
Medium
Justification
Routine demat auction affecting multiple securities due to delivery shortfalls. Impacts specific trades requiring auction settlement but is part of normal market operations.
Welcure Drugs & Pharmaceuticals Limited has allotted 11,23,58,200 bonus shares in the ratio of 1:10 (post share split from Rs. 10 to Re. 1 face value), with listing effective from October 20, 2025.
Impact
Medium
Severity
Medium
Justification
Standard corporate action involving bonus issue combined with share split. Significant for existing shareholders with 10% increase in shareholding. Medium impact as it affects share structure and liquidity.
Welcure Drugs & Pharmaceuticals Ltd has allotted 11,23,58,200 bonus equity shares in the ratio of 1:10, effective October 17, 2025, following a stock split from Rs. 10 to Re. 1 face value.
Impact
Medium
Severity
Medium
Justification
Corporate action affecting shareholding pattern and share capital structure; medium impact as it's a bonus issue combined with stock split for a single company
BSE Demat Auction settlement listing 100 scrips with their respective auction quantities for settlement number 737 dated October 17, 2025.
Impact
Medium
Severity
Medium
Justification
Regular demat auction circular affecting multiple securities with specific quantities to be auctioned for settlement obligations. Standard operational procedure with moderate market impact.
New ISIN number INE331C01025 assigned for sub-divided equity shares of Welcure Drugs & Pharmaceuticals Ltd, effective from October 16, 2025.
Impact
Medium
Severity
Medium
Justification
Routine corporate action involving ISIN change due to share sub-division. Affects existing shareholders and trading systems but is a standard procedural change.